Security Snapshot

Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS) Institutional Ownership

CUSIP: 171126204

13F Institutional Holders and Ownership History from Q3 2025 to Q3 2026

13F reference period

Q3 2026

Institutions Reporting

14

Shares (Excl. Options)

833.62KFull value: 833,617 · shares · 30 Sep 2026

Price

$21.01

The headline uses the Q3 2026 reference period after its reporting deadline. Available reports may still be incomplete or amended.

Save this security page for your next review

Watchlists follow companies and investors, across their share classes. Bookmark this page to revisit this specific CUSIP and its quarterly holders. If you create an account from here, we will bring you back after verification.

Latest holder snapshot 5 signals
Portfolio coverage rank
0%
Share change
-1,176
Value change
-$24,726
Number of holders
14
Issuer context Names, identifiers, and filing context for this profile. 3 identity fields
Shares outstanding
3,873,202
SEC-reported price per share
$20.29
Insider filing price
$20.29
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Filing notes and source

Key facts

  • PTHS - Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 171126204.
  • 14 institutions reported positions in Q3 2026.
  • 5 significant owners is listed from Schedule 13D/13G reporting.

Change

  • Holder count moved from 23 to 14 between Q2 2026 and Q3 2026.
  • SEC-reported value moved from
    $37.39MFull value: $37,392,417 · USD · 30 Jun 2026
    to
    $17.51MFull value: $17,514,078 · USD · 30 Sep 2026
    .

Research use

  • You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
  • 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Form 13F

Latest holder context comes from 14 institutions filings for Q3 2026.

Open SEC evidence

Security key

171126204

13F reference period

Q3 2026

13F holders

14

13D/G owners

5

CIK / CUSIP context first

13D/G owners

Significant owners

Large-stake holder rows connected to Schedule 13D/G evidence.

Rows
5
Security
PTHS
Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
LIGAND PHARMACEUTICALS INC 50% 0% $105,288,403 5,189,177 0% Ligand Pharmaceuticals Incorporated 30 Oct 2026
3i, LP 9.9% 0% $7,780,140 +$941,882 383,447 +14% 3i, LP 30 Sep 2026
Murchinson Ltd. 9.1% $7,840,000 280,000 Murchinson Ltd. 30 Sep 2025
Ikarian Capital, LLC 7.7% -8.8% $5,901,754 +$19,320 256,598 +0.33% Ikarian Capital, LLC 31 Mar 2026
Friedberg Ezra M 8.3% 250,121 Ezra Friedberg 01 Jul 2025
As of 30 Sep 2026, 14 institutional investors reported holding
833.62KFull value: 833,617 · shares · 30 Sep 2026
shares of Pelthos Therapeutics Inc. - Common Stock, par value $0.0001 per share (PTHS). This represents 22% of the company’s total
3.87MFull value: 3,873,202 · shares · Stored outstanding share count
outstanding shares.

13F concentration

Top 14 institutional shareholders

Largest 13F positions for this security by reported shares and value.

Top holder share
22%
Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Murchinson Ltd. 8% 311,019 +2.2% 4% $6,534,509
AIGH Capital Management LLC 6.6% 256,012 -22% 0.61% $5,378,812
VANGUARD CAPITAL MANAGEMENT LLC 2.5% 95,316 -1.9% 0% $2,002,589
WEXFORD CAPITAL LP 2.2% 84,616 +278% 0.24% $1,777,782
Knott David M Jr 0.46% 17,644 -20% 0.2% $370,700
GEODE CAPITAL MANAGEMENT, LLC 0.43% 16,575 +13% 0% $348,239
1492 Capital Management LLC 0.38% 14,577 +40% 0.1% $306,263
Pale Fire Capital SE 0.33% 12,919 0% 0.02% $271,428
STATE STREET CORP 0.28% 10,800 +10% 0% $226,908
VANGUARD FIDUCIARY TRUST CO 0.27% 10,363 +5% 0% $217,727
China Universal Asset Management Co., Ltd. 0.06% 2,360 +9.3% 0% $49,371
Vanguard Global Advisers, LLC 0.04% 1,370 0% $28,784
Farther Finance Advisors, LLC 0% 40 0% 0% $840
MORGAN STANLEY 0% 6 0% $126

Quarter history

Institutional holders across reporting periods

Holder count, reported shares/value, and median price by quarter.

Periods
5
Headline period
Q3 2026
Rows shown
1-5 of 5
Period 13F Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2026 Q3 833,617 $17,514,078 -$24,726 $21.01 14
2026 Q2 1,323,157 $37,392,417 +$11,624,481 $28.26 23
2026 Q1 912,311 $19,167,664 -$424,416 $21.01 17
2025 Q4 899,359 $27,880,129 +$13,536,994 $31.00 15
2025 Q3 462,762 $12,957,336 +$12,957,336 $28.00 14
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .